Skip to main content

Advertisement

Table 4 Drugs with Level-1 MDIs with the most clinical significance

From: Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan

Drugs Frequency Mechanisms of MDI
Tramadol 42 Concomitant administration of methadone and tramadol may result in withdrawal symptoms; methadone (moderate CYP 2D6 inhibitor) may decrease the metabolism of tramadol
Chlorpromazine 22 The concomitant use of methadone and chlorpromazine may cause additive CNS and respiratory depression
Levofloxacin 16 Levofloxacin may increase the QTc prolonging effects of methadone
Prochlorperazine 12 The concomitant use of methadone and prochlorperazine may cause additive CNS and respiratory depression
Moxifloxacin 6 Moxifloxacin may increase the QTc prolonging effects of methadone
Ciprofloxacin 5 Ciprofloxacin may increase the QTc prolonging effects of methadone
Haloperidol 5 Haloperidol may increase the QTc prolonging effects of methadone
Buprenorphine 1 Concomitant administration of methadone and buprenorphine may result in withdrawal symptoms
Droperidol 1 Droperidol may increase the QTc prolonging effects of methadone
Nalbuphine 1 Concomitant administration of methadone and nalbuphine may result in withdrawal symptoms
Thioridazine 1 The concomitant use of methadone and thioridazine may cause additive CNS and respiratory depression